TABLE 1.
Detailed Renal and Clinical Outcomes of Indexed by Osmotherapy Use
| Kidney Function and Outcome | Mannitol (n = 43) | No Mannitol (n = 525) | p | HTS (n = 170) | No HTS (n = 398) | p |
|---|---|---|---|---|---|---|
| Any AKI after 2 d, n (%) | 15 (35) | 57 (11) | < 0.001 | 37 (22) | 35 (9) | < 0.001 |
| Absolute change in creatinine between day 3 and 5 (µmol/L), median (interquartile range) | 1 (4.5–11) | –2 (–7 to 3) | 0.003 | –1 (–6 to 5) | –2 (–7 to 2) | 0.005 |
| Proportional change in creatinine between day 3 and day 5 (%), median (interquartile range) | 1 (–5 to 18) | –3 (–10 to 4) | 0.003 | –0.1 (–9 to 9) | –3 (–10 to 3) | 0.003 |
| Median highest creatinine, median (interquartile range) | 73 (63–97) | 72 (62–84) | 0.25 | 72 (64–89) | 72 (62–83) | 0.04 |
| Days to highest Kidney Disease Improving Global Outcome stage, median (interquartile range) | 6 (5–9) | 7 (5–10) | 0.53 | 7 (5–9) | 7 (5–11) | 0.96 |
| Renal replacement therapy, n (%) | 1 (2) | 6 (1) | 0.50 | 3 (2) | 4 (1) | 0.45 |
| Lack of AKI at ICU discharge, n (%) | 35 (81) | 509 (97) | < 0.001 | 157 (92) | 387 (97) | < 0.008 |
| ICU LOS, median (interquartile range) | 14 (8–22) | 13 (8–20) | 0.62 | 13 (9–21) | 13 (6–20) | 0.17 |
| Hospital LOS, median (interquartile range) | 27 (9–62) | 26 (15–46) | 0.96 | 28 (14–51) | 25 (15–43) | 0.38 |
| ICU death, n (%) | 12 (28) | 45 (9) | < 0.001 | 30 (18) | 27 (7) | < 0.001 |
| Hospital death, n (%) | 14 (33) | 54 (10) | < 0.001 | 33 (19) | 35 (9) | < 0.001 |
| 6-mo mortality, n (%) | 14 (33) | 62 (12) | < 0.001 | 36 (21) | 40 (10) | < 0.001 |
| Good outcome neurologic outcome (Glasgow Outcome Scale extended 5–8), n (%) | 13 (31) | 289 (56) | 0.002 | 75 (44) | 227 (58) | 0.003 |
AKI = acute kidney injury, HTS = hypertonic saline, LOS = length of stay.
Data regarding creatinine at day 5 were missing in 59 patients on day 5 and in 23 patients on day 3.